Chemistry:Ilaprazole
![]() | |
Clinical data | |
---|---|
Trade names | Noltec |
Routes of administration | Oral |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C19H18N4O2S |
Molar mass | 366.44 g·mol−1 |
3D model (JSmol) | |
| |
|
Ilaprazole (trade name Noltec) is a proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD)[1] and duodenal ulcer.[2][3]
It is available in strengths of 5, 10, and 20 mg.
Clinical studies show that ilaprazole is at least as potent a PPI as omeprazole when taken in equivalent doses. Studies also showed that ilaprazole significantly prevented the development of reflux oesophagitis.
Ilaprazole is developed by Il-Yang Pharmaceutical (Korea), and is still under clinical trials with US FDA. It has launched in Korea and China for the treatment of gastric ulcer, duodenal ulcer, gastroesophageal reflux disease and erosive esophagitis.[4]
Ilaprazole is sold in Mexico by Chinoin Pharmaceuticals under the brand name Norutec.[5]
References
- ↑ "Ilaprazole for the treatment of gastro-esophageal reflux". Expert Opinion on Pharmacotherapy 17 (15): 2107–13. October 2016. doi:10.1080/14656566.2016.1232389. PMID 27598861.
- ↑ "Ilaprazole: Is this a superior proton pump inhibitor for duodenal ulcer?". Tropical Gastroenterology 34 (2): 95–8. 2013. doi:10.7869/tg.2012.105. PMID 24377157.
- ↑ "Efficacy of ilaprazole in the treatment of duodenal ulcers: a meta-analysis". World Journal of Gastroenterology 20 (17): 5119–23. May 2014. doi:10.3748/wjg.v20.i17.5119. PMID 24803828.
- ↑ Clinical trial number NCT00952978 for "Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 3)" at ClinicalTrials.gov
- ↑ "Norutec". Chinoin Pharmaceuticals. https://www.actuamed.com.mx/marca/713471.
![]() | Original source: https://en.wikipedia.org/wiki/Ilaprazole.
Read more |